Navigation Links
HLTH Announces Agreement to Sell ViPS Unit to General Dynamics for $225 Million

ELMWOOD PARK, N.J., June 3 /PRNewswire-FirstCall/ -- HLTH Corporation (Nasdaq: HLTH) today announced that it has entered into a definitive agreement to sell its ViPS segment to General Dynamics Information Technology, Inc., a wholly-owned subsidiary of General Dynamics Corporation (NYSE: GD) for $225 million in cash. The closing is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Act.

ViPS provides healthcare data management, analytics, decision-support and process automation solutions and related information technology services to governmental, Blue Cross Blue Shield and commercial healthcare payers. ViPS' solutions and services help its clients improve patient outcomes, increase customer satisfaction and reduce costs.

Merger with WebMD

As previously announced, HLTH and WebMD entered into a definitive merger agreement on February 20, 2008. The agreement provides that HLTH will be merged into WebMD, with each outstanding share of HLTH common stock to be converted into 0.1979 shares of WebMD common stock and $6.89 in cash, subject to certain adjustments. Completion of the merger is conditioned upon, among other things, completion of SEC review of the proxy statement/prospectus, the completed sale of either ViPS or Porex and the approval of the stockholders of both HLTH and WebMD. HLTH and WebMD currently expect to hold stockholder meetings in September to seek necessary approvals.

Jefferies & Company, Inc. acted as exclusive financial advisor to HLTH Corporation in the sale of ViPS and has also been engaged to complete the sale process for Porex.

About HLTH

HLTH Corporation (Nasdaq: HLTH) owns 84% of WebMD Health Corp. (Nasdaq: WBMD). WebMD is the leading provider of health information services for consumers, physicians, healthcare professionals, employers and health plans through its public and private online portals and health-focused publications. HLTH also owns Porex, a developer, manufacturer and distributor of proprietary porous plastic products and components used in healthcare, industrial and consumer applications.

This press release does not constitute an offer of any securities for sale. In connection with the proposed merger, HLTH and WebMD expect to file, with the SEC, a proxy statement/prospectus as part of a registration statement regarding the proposed transaction. Investors and security holders are urged to read the proxy statement/prospectus because it will contain important information about HLTH and WebMD and the proposed transaction. Investors and security holders may obtain a free copy of the definitive proxy statement/prospectus and other documents when filed by HLTH and WebMD with the SEC at or or Investors and security holders are urged to read the proxy statement, prospectus and other relevant material when they become available before making any voting or investment decisions with respect to the merger.

All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding: the closing of the sale transaction relating to ViPS (the "ViPS Sale"); the merger transaction between HLTH and WebMD (the "Merger Transaction"); and the potential sale transaction with respect to Porex (the "Potential Porex Sale"). These statements speak only as of the date of this press release, are based on HLTH's current plans and expectations, and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward- looking statements. These risks and uncertainties include those relating to: changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet, information technology and plastics industries. Further information about these matters can be found in our other Securities and Exchange Commission filings. In addition, there can be no assurances: regarding whether HLTH will be able to complete the Merger Transaction or the ViPS Sale or as to the timing of such transactions; or regarding the timing or terms of the Potential Porex Sale. Except as required by applicable law or regulation, we do not undertake any obligation to update our forward-looking statements to reflect future events or circumstances.

WebMD(R), WebMD Health(R), POREX(R) and ViPS(SM) are trademarks of HLTH Corporation or its subsidiaries.

SOURCE HLTH Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Insulet Announces Development Agreement for the First Non-Diabetes Drug Delivery Application for the OmniPod System
2. Immtech Announces Results From Hepatitis C Discovery Program
3. Axsun Technologies Announces Strategic Supply Agreement for Integrated OCT Engines with Lantis Laser for Dental Imaging Applications
4. Antipodean Pharmaceuticals Announces FDA Acceptance of IND for MitoQ(R)
5. Milliman Announces Encore Webinar on Practical Uses of Lifestyle-Based Analytics (LBA) in Risk Selection
6. Katzen Eye Group Announces a New Option in Vision Correction Technology for Patients
7. AMA Insurance Agency Announces Launch of Consultations(SM)
8. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSAnchor(TM) Grip Nitinol Soft Tissue Anchor
9. Animal Dermatology Clinic - San Diego Announces Dr. Brett Wildermuth, DVM, Achieves Diplomate Status With the American College of Veterinary Dermatology
10. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming WUWHS Conference
11. Medical Simulation Corporation Announces Partnership With Seattle Science Foundation
Post Your Comments:
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... Finnleo, ... through Christmas Eve on several models of traditional and far-infrared saunas. , ... Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at ... hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety ... fuller hair, without the need for surgery, prescription pills, or topical foams. , ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, ... Two Organizations, One Beat ” campaign. The partnership between the two groups began in ... in MAP International’s cause. , MAP International was founded in 1954 and is an ...
(Date:11/25/2015)... ... 2015 , ... Dental professionals who would like to become more proficient on ... Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on ... co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to ...
(Date:11/25/2015)... IL (PRWEB) , ... November 25, 2015 , ... The ... announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex ... Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... firms (the "New Investors"), pursuant to which BioLight and ... in BioLight,s IOPtima Ltd. subsidiary ("IOPtima") via a private ... global commercialization of its innovative IOPtimate™ system used in ... a regulatory approval pathway process for the IOPtimate™ system ...
Breaking Medicine Technology: